US 10563184
Regulation of gene expression using engineered nucleases
granted A61KA61K2035/124A61K35/28
Quick answer
US patent 10563184 (Regulation of gene expression using engineered nucleases) held by Sangamo Therapeutics, Inc. expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K2035/124, A61K35/28, A61K38/00, A61P